Vericel Announces Appointment of Sean C. Flynn as Vice President and General Counsel
07 November 2019 - 1:00AM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
for the sports medicine and severe burn care markets, today
announced the appointment of Sean C. Flynn as Vice President and
General Counsel.
Mr. Flynn has served as corporate and litigation counsel for
nearly 20 years, in both the public and private sectors.
Prior to joining Vericel, Mr. Flynn held the position of Vice
President and General Counsel of Verastem, Inc., where he was
responsible for all legal matters and supported the launch and
commercialization of Copiktra®. Mr. Flynn also held the
position of Associate General Counsel and Chief Compliance Officer
for ABIOMED, Inc. during a period of rapid revenue and market
growth. In that capacity, Mr. Flynn handled a wide assortment
of business and legal matters for the organization, while
maintaining responsibility for the compliance readiness of the
company on a global scale. Prior to joining ABIOMED, Mr.
Flynn served for seven years as a federal prosecutor with both the
United States Attorney’s Offices for the Eastern District of
California and the Eastern District of New York. Mr. Flynn
began his legal career as a litigator with Bingham McCutchen LLP,
after clerking for the Honorable Ruggero J. Aldisert, Senior
Circuit Judge, United States Court of Appeals for the Third
Circuit. Prior to beginning his legal career, Mr. Flynn
served as an air defense artillery officer for the United States
Army, having graduated from the United States Military Academy at
West Point in 1995.
“Sean brings a unique blend of legal expertise spanning
publicly-traded medical device and biopharmaceuticals companies
along with years as a federal prosecutor and commercial trial
attorney,” said Nick Colangelo, president and chief executive
officer of Vericel. “Sean will provide strong legal guidance
and play a key role in the execution of our long-term growth
strategy.”
About Vericel CorporationVericel is a leader in
advanced therapies for the sports medicine and severe burn care
markets. The company markets two cell therapy products in the
United States. MACI® (autologous cultured chondrocytes on
porcine collagen membrane) is an autologous cellularized scaffold
product indicated for the repair of symptomatic, single or multiple
full-thickness cartilage defects of the knee with or without bone
involvement in adults. Epicel® (cultured epidermal
autografts) is a permanent skin replacement for the treatment of
patients with deep dermal or full thickness burns greater than or
equal to 30% of total body surface area. The company also
holds an exclusive license for North American commercial rights to
NexoBrid®, a registration-stage biological orphan product for
debridement of severe thermal burns. For more information,
please visit the company's website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. NexoBrid® is a registered trademark of MediWound
Ltd. and is used under license to Vericel Corporation. © 2019
Vericel Corporation. All rights reserved.
Global Media Contacts:David SchullRusso
Partners LLCDavid.schull@russopartnersllc.com+1 212-845-4271
(office)+1 858-717-2310 (mobile)
Investor Contacts:Lee SternSolebury
Troutlstern@troutgroup.com+1 646-378-2922
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024